NextCure, Inc. (NASDAQ:NXTC) Receives Consensus Rating of “Hold” from Brokerages

NextCure, Inc. (NASDAQ:NXTC) has been assigned an average rating of “Hold” from the five analysts that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation and three have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $23.00.

A number of research analysts have recently commented on the stock. Zacks Research downgraded shares of NextCure from a “hold” rating to a “strong sell” rating in a research report on Wednesday, May 6th. Weiss Ratings restated a “sell (d-)” rating on shares of NextCure in a research note on Monday, April 27th.

Institutional Trading of NextCure

Hedge funds have recently modified their holdings of the stock. Marshall Wace LLP acquired a new stake in shares of NextCure during the 4th quarter worth about $160,000. Millennium Management LLC acquired a new stake in shares of NextCure during the 4th quarter worth about $185,000. Geode Capital Management LLC lifted its stake in shares of NextCure by 18.6% during the 4th quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock worth $329,000 after buying an additional 3,636 shares during the last quarter. Renaissance Technologies LLC raised its stake in NextCure by 18.7% in the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock worth $477,000 after purchasing an additional 5,300 shares in the last quarter. Finally, Boothbay Fund Management LLC acquired a new stake in NextCure in the 4th quarter worth about $988,000. Institutional investors and hedge funds own 42.65% of the company’s stock.

NextCure Price Performance

Shares of NXTC opened at $3.38 on Tuesday. The firm has a 50-day moving average of $9.91 and a 200-day moving average of $11.45. NextCure has a one year low of $2.83 and a one year high of $15.74. The company has a market cap of $12.20 million, a PE ratio of -0.20 and a beta of 1.31.

NextCure (NASDAQ:NXTC) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.87) EPS for the quarter, beating analysts’ consensus estimates of ($2.10) by $0.23. Analysts expect that NextCure will post -7.91 earnings per share for the current year.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.